Literature DB >> 22209746

Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET(A)-PLCβ-PKCε pathway.

Ping-Chih Ho1, Yao-Chen Tsui, Yi-Wei Lin, Shawna D Persaud, Li-Na Wei.   

Abstract

The physiological signal activating cytoplasmic accumulation of nuclear receptor interacting protein 140 (RIP140) in adipocytes was unclear. We uncover that endothelin-1 (ET-1) promotes cytoplasmic accumulation of RIP140 in 3T3-L1 adipocytes. We determine ET-1's signal transduction pathway in adipocytes, which is by activating ET(A) receptor-PLCβ-nuclear PKCε. Blocking this pathway in 3T3-L1 adipocyte cultures, by treating cells with an ET(A) antagonist, inhibiting PLCβ, or silencing PKCε, reduces ET-1-stimulated cytoplasmic accumulation of RIP140. In a HFD-fed obese mouse model, administration of a selective ET(A) antagonist, ambrisentan, effectively dampens cytoplasmic accumulation of RIP140 in the epididymal adipose tissue and reduces HFD-caused adipocyte dysfunctions. Importantly, ambrisentan improves blood glucose control and reduces the severity of hepatic steatosis in HFD-fed mice. This study reports a physiological signal that stimulates nuclear export of RIP140 in adipocytes and provides evidence for a strategy using selective ET(A) antagonist to treat obesity-induced insulin resistance and, possibly, other metabolic disorders. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209746      PMCID: PMC3288750          DOI: 10.1016/j.mce.2011.12.003

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  31 in total

1.  Elevated plasma endothelin in patients with diabetes mellitus.

Authors:  K Takahashi; M A Ghatei; H C Lam; D J O'Halloran; S R Bloom
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

2.  The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes.

Authors:  K Ishibashi; T Imamura; P M Sharma; S Ugi; J M Olefsky
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

3.  TLR4 links innate immunity and fatty acid-induced insulin resistance.

Authors:  Hang Shi; Maia V Kokoeva; Karen Inouye; Iphigenia Tzameli; Huali Yin; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

Review 4.  Inflammation, stress, and diabetes.

Authors:  Kathryn E Wellen; Gökhan S Hotamisligil
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Negative regulation of adiponectin secretion by receptor interacting protein 140 (RIP140).

Authors:  Ping-Chih Ho; Li-Na Wei
Journal:  Cell Signal       Date:  2011-08-18       Impact factor: 4.315

6.  Cytoplasmic receptor-interacting protein 140 (RIP140) interacts with perilipin to regulate lipolysis.

Authors:  Ping-Chih Ho; Ya-Shan Chuang; Chen-Hsiang Hung; Li-Na Wei
Journal:  Cell Signal       Date:  2011-04-09       Impact factor: 4.315

7.  Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes.

Authors:  K I Ishibashi ; T Imamura; P M Sharma; J Huang; S Ugi; J M Olefsky
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 8.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

Review 9.  Insulin sensitivity: modulation by nutrients and inflammation.

Authors:  Simon Schenk; Maziyar Saberi; Jerrold M Olefsky
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 10.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

View more
  7 in total

Review 1.  Understanding the basis of auriculocondylar syndrome: Insights from human, mouse and zebrafish genetic studies.

Authors:  David E Clouthier; Maria Rita Passos-Bueno; Andre L P Tavares; Stanislas Lyonnet; Jeanne Amiel; Christopher T Gordon
Journal:  Am J Med Genet C Semin Med Genet       Date:  2013-10-04       Impact factor: 3.908

Review 2.  Biological activities of receptor-interacting protein 140 in adipocytes and metabolic diseases.

Authors:  Ping-Chih Ho; Li-Na Wei
Journal:  Curr Diabetes Rev       Date:  2012-11

3.  Cellular retinoic acid binding protein I mediates rapid non-canonical activation of ERK1/2 by all-trans retinoic acid.

Authors:  Shawna D Persaud; Yi-Wei Lin; Cheng-Ying Wu; Hiroyuki Kagechika; Li-Na Wei
Journal:  Cell Signal       Date:  2012-09-07       Impact factor: 4.315

4.  Receptor-interacting protein 140 attenuates endoplasmic reticulum stress in neurons and protects against cell death.

Authors:  Xudong Feng; Kelly A Krogh; Cheng-Ying Wu; Yi-Wei Lin; Hong-Chieh Tsai; Stanley A Thayer; Li-Na Wei
Journal:  Nat Commun       Date:  2014-07-28       Impact factor: 14.919

5.  Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice.

Authors:  Li Feng; Songhua Wang; Feng Chen; Cheng Zhang; Qiao Wang; Yuting Zhao; Zifeng Zhang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-02       Impact factor: 3.168

6.  Transcriptional Regulation by Nuclear Corepressors and PGC-1α: Implications for Mitochondrial Quality Control and Insulin Sensitivity.

Authors:  Zhengtang Qi; Shuzhe Ding
Journal:  PPAR Res       Date:  2012-12-06       Impact factor: 4.964

7.  All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation.

Authors:  Shawna D Persaud; Sung Wook Park; Mari Ishigami-Yuasa; Naoko Koyano-Nakagawa; Hiroyuki Kagechika; Li-Na Wei
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.